Diet and Fasting Beat Drugs for Fatty Liver Disease Management
A 2025 integrative review finds Mediterranean, plant-based, and fasting diets reduce liver fat and metabolic dysfunction in MASLD patients.
Summary
With no approved drug for metabolic fatty liver disease (MASLD), this 2025 integrative review synthesizes evidence on dietary and fasting interventions. The Mediterranean diet emerged as the top performer, reducing liver fat and BMI by ~18% in six months and cutting metabolic syndrome prevalence by 48% over two years. Plant-based and DASH diets also showed meaningful benefits. Fasting strategies—including intermittent fasting, time-restricted eating, alternate-day fasting, and the fasting-mimicking diet—improved insulin sensitivity, reduced intrahepatic fat, and promoted fat oxidation. The review concludes that these non-pharmacological strategies are practical first-line tools, though long-term adherence and protocol standardization remain challenges.
Detailed Summary
MASLD (formerly NAFLD) affects over 30% of adults globally and is tightly linked to obesity, insulin resistance, and type 2 diabetes. Despite its rising prevalence—reaching 46% in the MENA region and affecting 77% of U.S. teenagers with suspected disease—no pharmacological treatment has received regulatory approval, making lifestyle modification the primary intervention. This integrative review, conducted by researchers at the University of Balamand, synthesized human studies from PubMed, Scopus, and Web of Science through January 2025, covering RCTs, prospective studies, systematic reviews, and meta-analyses.
The Mediterranean diet (MedDiet) received the strongest evidence base. A six-month RCT in 46 MASLD adults showed an 18% reduction in both BMI and liver fat score alongside improved lipid profiles. A two-year Italian RCT demonstrated a 48% net reduction in metabolic syndrome prevalence. A meta-analysis of 3,037 participants confirmed improvements in liver enzymes, hepatic steatosis, liver stiffness, and the fatty liver index, with caloric restriction amplifying these effects. A polyphenol-enriched 'Green-MedDiet' further reduced intrahepatic fat versus standard MedDiet. Low-glycemic index and low-carbohydrate variants of the MedDiet added benefits by reducing postprandial glucose spikes and improving insulin sensitivity.
Plant-based diets also demonstrated significant hepatoprotective effects. Higher adherence to a healthful plant-based diet index (hPDI) was associated with reduced MASLD risk, while unhealthful plant-based diet scores (uPDI) showed the opposite. The DASH diet, rich in fruits, vegetables, whole grains, and low-fat dairy, reduced liver enzymes, inflammatory markers, and oxidative stress in multiple RCTs, with one 8-week trial showing significant reductions in ALT, AST, triglycerides, and insulin resistance.
Fasting interventions garnered growing attention. Intermittent fasting (IF) protocols, including the 5:2 method and 16:8 time-restricted eating (TRE), reduced intrahepatic triglycerides, improved liver enzymes, and enhanced insulin sensitivity. Alternate-day fasting (ADF) showed comparable weight and metabolic improvements to continuous caloric restriction. The fasting-mimicking diet (FMD), a 5-day monthly low-calorie protocol, reduced liver fat and improved cardiometabolic markers in both animal models and early human trials. These fasting strategies work mechanistically by activating autophagy, promoting ketogenesis, reducing hepatic de novo lipogenesis, and improving circadian metabolic alignment.
The review emphasizes that combining dietary quality with structured eating windows or fasting periods may produce synergistic benefits. However, the authors caution that most studies are short-term, use heterogeneous protocols, and lack liver biopsy confirmation of histological improvement. Long-term adherence, cultural dietary differences, and individual patient variability remain practical barriers. Future research should prioritize standardized protocols, longer follow-up, and head-to-head comparisons of dietary and fasting strategies.
Key Findings
- Mediterranean diet reduced liver fat and BMI by ~18% in 6 months and metabolic syndrome by 48% over 2 years.
- Polyphenol-enriched 'Green-MedDiet' outperformed standard MedDiet in reducing intrahepatic fat.
- DASH diet significantly lowered ALT, AST, triglycerides, and insulin resistance within 8 weeks.
- Intermittent fasting and time-restricted eating reduced intrahepatic triglycerides and improved insulin sensitivity.
- Fasting-mimicking diet reduced liver fat and cardiometabolic markers in early human and animal studies.
Methodology
Integrative narrative review searching PubMed, Scopus, and Web of Science through January 2025. Included human RCTs, prospective and observational studies, systematic reviews, and meta-analyses reporting liver or metabolic outcomes. Animal studies, non-English publications, and studies lacking relevant outcomes were excluded; qualitative synthesis was used due to heterogeneity across study designs.
Study Limitations
Most included studies are short-term with heterogeneous fasting protocols and dietary definitions, limiting direct comparisons. Few trials used liver biopsy as an endpoint, relying instead on imaging or enzyme surrogates. Long-term adherence data are sparse, and findings may not generalize across ethnic, socioeconomic, and cultural populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.